A Phase 1 interventional study of HRS-2129 Tablets and HRS-2129 Placebo in Diabetic Peripheral Neuropathic Pain, sponsored by Shandong Suncadia Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Neuralgia with a site in China — 17 open to participants now, 17 under way, 1 of them phase 3. Neuralgia · China.
Among the 41 studies in Neuralgia with a site in China, this one is the 15th largest by planned enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2026, is one of 2 in phase 1, reaches primary completion later than 9 of the 16 other live ones, and was the 36th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →17 of the 41 studies in Neuralgia with a site in China are open now. Recruiting first, the newest first:
Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. · Sites in China
Ages 18+
Nanchong Central Hospital · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 6 · Phase 4 2
First in 2006; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 168 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 147 across the 31 interventional studies, 300 across the 10 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuralgia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06766916Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityCrisugabalin for Radiotherapy-Related Neuropathic Pain | 2026-11-30 |
| NCT06596681Beijing Tiantan HospitalA Study of the Safety and Tolerability of GA in the Treatment of Patients With Refractory Neuropathic Pain | 2026-12-31 |
| NCT07740707Nanchong Central HospitalShort-term SCS for Refractory Diabetic Foot Neuropathic Pain | 2027-03-01 |
| NCT07148388Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAccelerated Intermittent Theta Burst Stimulation (AiTBS)on Neuropathic Pain | 2027-09-01 |
| NCT07699770Tang-Du HospitalCrisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial | 2027-10-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Neuralgia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-2129 Tablets · Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo
Drug: HRS-2129 Tablets · Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo
Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules
Drug: HRS-2129 Placebo · Drug: Pregabalin Capsules Placebo
HRS-2129 tablets.
HRS-2129 placebo.
Pregabalin capsules.
Pregabalin capsules placebo.
Compare the change from baseline in Average Daily Pain Score (ADPS) between HRS-2129 and placebo at Week 4.
The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.
Time frame: Baseline and Week 4.
Compare the response rate between HRS-2129 and placebo at Week 4 (Proportion of subjects whose ADPS decreased by ≥ 30% and ≥ 50% from baseline).
Ratio of participants responding to treatment, as measured by Average Daily Pain Score (ADPS) reduction from baseline. The ADPS is used to determine categorical response rates.
Time frame: Baseline and Week 4.
Compare the change from baseline in ADPS between HRS-2129 and placebo at Week 1 to 4.
The mean change in Average Daily Pain Score (ADPS) was measured using a 11-point numeric rating scale (NRS; 0 \[no pain\] to 10 \[worst possible pain\]). The rating averaged over a 7-day period and was based on entries in patients' daily pain diaries.
Time frame: From Week 1 to Week 4.
Compare the change from baseline in Visual Analog Scale (VAS) between HRS-2129 and placebo at Week 4.
VAS, in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain.
Time frame: Baseline and Week 4.
Compare the change from baseline in Short-Form McGill Pain Questionnaire (SF-MPQ) between HRS-2129 and placebo at Week 4.
Participants rate their pain in three parts of the questionnaire, which are combined into a single pain intensity score: Part 1 - 11 descriptors of pain intensity, and 4 descriptors of emotions, on a scale of 0 (none) to 3 (severe); Part 2 - a Visual Analog Scale (VAS), in which the participant rates pain on a 100 mm-long horizontal line, where 0 mm = no pain and 100 mm = worst possible pain; Part 3 - a Present Pain Intensity index in which the participant rates present pain intensity on a scale of 0 (no pain) to 5 (most intense pain).
Time frame: Baseline and Week 4.
Compare the Patient Global Impression of Change (PGIC) between HRS-2129 and placebo at Week 4.
Patient Global Impression of Change (PGIC) on a 7-point categorical scale, where 1 = very much improved and 7 = very much worse.
Time frame: At Week 4.
Compare the change from baseline in Average Daily Sleep Interference score (ADSIS) between HRS-2129 and placebo at Week 4.
The sleep interference scores on a scale of 0-10, where 0 = pain did not interfere with sleep to 10 = pain completely interfered with sleep. The weekly ADSIS is based on participants daily sleep interference scores.
Time frame: Baseline and Week 4.
Number and severity of serious adverse events (SAEs).
To evaluate the safety of HRS-2129 during the trial.
Time frame: From Week 1 to Week 6.
Number and severity of adverse events (AEs).
To evaluate the safety of HRS-2129 during the trial.
Time frame: From Week 1 to Week 6.
Population Pharmacokinetics (PopPK) characteristics of HRS-2129 in Chinese patients with diabetic peripheral neuropathic pain - Serum concentration of HRS-2129.
Population Pharmacokinetics (PopPK) will be determined by measuring serum concentration of HRS-2129.
Time frame: From Day 0 to Day 30.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Sep 2026, 6 months after the start.
Of 36 phase 1 interventional studies under Neuralgia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-2129
Shandong Suncadia Medicine Co., Ltd. →